Clinical Trial Update: Prazosin for Agitation in Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for prazosin in agitation associated with Alzheimer's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Disruptive Behavior

Drugs mentioned

• Prazosin (prazosin)

Snippet

Sponsor: Alzheimer's Disease Cooperative Study (ADCS) | Conditions: Alzheimer's Disease, Disruptive Behavior | Phase 2 | Status: COMPLETED | Results posted: 2023-02-06